This site provides INTERCEPT product information for International audiences .

PATHOGEN INACTIVATION

Protect Patients

Each and every day, blood product transfusions save lives. Transfusions, however, are not without risk

Reducing Infectious Risk

Blood may be contaminated with harmful bacteria, viruses and parasites which can lead to transfusion-transmitted infectious diseases (TTID)

Despite the existing best efforts (donor selection, testing, limiting storage time and quarantine of blood components) there is still an intolerable level of risk that cannot be ignored. INTERCEPT™ Platelets and Plasma present a proactive approach in which viruses, bacteria and parasites are efficiently inactivated, providing improved blood safety when TTID risk is unknown or confirmed.

Why Blood Safety Matters
Bacterial Risk
Learn more
Elevate Patient Care
Risk from Viruses & Emerging Pathogens
Learn more
Mechanism of Action
Parasitic Risk
Learn more

Reducing Non-Infectious Risk

Residual blood components may trigger adverse reactions
  • Transfusion associated graft-vs-host disease (TA-GvHD)
  • Pulmonary injury including acute respiratory distress syndrome (ARDS)
  • Allergic/anaphylactic (ATR) Reactions/Hypersensitivity Reactions (HTR)
  • Febrile non-haemolytic reactions (FNHTR)
  • Transfusion-related acute lung injury (TRALI)
Residual leucocytes, leucocyte associated molecules, inflammatory molecules (chemokines and cytokines), IgA, anti HLA and HNA antibodies in donated blood and blood products, may increase the risk of adverse reactions.
The INTERCEPT™ Blood System for platelets and plasma may reduce the frequency of such adverse events in transfused patients.1,2 Additionally, the usage of Platelet Additive Solution (PAS) can further reduce the incidence of transfusion reactions by lowering the quantity of plasma proteins and antibodies. The INTERCEPT™ System is officially approved as an alternative to irradiation.3,4
Learn more

You may also be interested in

Why Blood Safety Matters
Improve Availability
Learn more
Elevate Patient Care
Safeguard Clinical Outcomes
Learn more
Mechanism of Action
Provide Operational Benefits
Learn more
References:

  1. Jutzi M et al., 2018. Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland. Transfus Med Hemother 45: 151-156
  2. Cazenave JP et al., 2011. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 51: 622-629
  3. The INTERCEPT Blood System for Platelets Technical Data Sheet, Cerus Corporation.
  4. Li M et al., 2022. Is pathogen reduction an acceptable alternative to irradiation for risk mitigation of transfusion-associated graft versus host disease? Transfus Apher Sci 61: 103404

There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19, and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT™ process. For a full list of warnings, precautions for use and pathogens inactivated, please refer to the Technical Data Sheet and Instructions for Use found in the resource section of this website.